计算溶液所需的质量、体积或浓度。
,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Verucerfont is a corticotropin-releasing factor receptor 1 ( CRF1 ) antagonist with IC 50 s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.
In Vivo
Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline) . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:IC50: 6.1 nM (CRF1), >1000 nM (CRF2), >1000 nM (CRF-BP)
| ALogP | 4.5 |
|---|
H302: 吞食有害
H361: 怀疑破坏生育力或未出生的孩子